I'm Betsy, wife of Tom, who was diagnosed this past January with subcutaneous stage IV, no known primary, BRAF negative.
As far as the scans show, there are two subcutaneous masses, with no mets to organs.
Tom has received his first infusion of Keytruda, with the second infusion happening tomorrow. Tom is under the care of Dr Sunil Reddy at Stanford.
We plan to ask Dr Reddy this question, but I'm wondering if anyone here has insight into why monotherapies are offered in favor of combo therapies? I mean, why not attack the cancer with multiple immunotherapies?
If Keytruda helps the T-cells be more effective, why not AT THE SAME TIME also work to increase the number of T-cells in Tom's body?
I don't get it.
Thanks in advance for your thoughts on this. I've been lurking for a while, and I'm in awe of your strength and courage.
Best wishes to all of you!